Skip to content
Article Rich – Lifestyle
Author:
Abbott
Late-breaking one-year data show Abbott’s next-generation Amulet 360™ device continues to demonstrate high rates of left atrial appendage closure and low incidence of stroke
November 2, 2026
Abbott’s TECTONIC clinical trial demonstrates strong 30-day outcomes and high procedural success for its investigational SonicForce™ Coronary Intravascular Lithotripsy System
November 1, 2026
Abbott initiates pivotal trial for Cephea™ device, an innovative treatment for mitral heart valve disease
October 29, 2026
Abbott launches whole-genome sequencing Oncodetect® molecular residual disease (MRD) test to detect traces of cancer during and after treatment
October 26, 2026
Abbott presents new ESMO data showing 30-percent absolute improvement in sensitivity with the whole-genome sequencing Oncodetect® test in colorectal cancer
October 23, 2026
Abbott announces its intention to separate its global Nutrition business into an independent, publicly traded company
October 21, 2026
Abbott Reports Third-Quarter 2026 Results and Reaffirms Full-Year EPS Guidance
October 21, 2026
Abbott introduces Ensure® Max Protein 3-in-1 Muscle Support, bringing the benefits of a supplement stack into one scoop
October 7, 2026
Abbott receives FDA approval for new CardioMEMS HF System capabilities that help patients engage in the care of their heart condition
October 5, 2026
Abbott hosts conference call for third-quarter earnings
September 30, 2026
1
2
3
Next Page
→